The global CRISPR gene editing market size was valued at USD 5.35 billion in 2025 and is projected to grow from USD 6.68 billion in 2026 to USD 39.29 billion by 2034, registering a CAGR of 24.8% during the forecast period from 2026 to 2034. North America dominated the CRISPR gene editing market with a market share of 42.5% in 2025.
CRISPR gene editing is an advanced genome-editing technology that enables scientists to precisely modify, delete, or replace specific DNA sequences within the genome of living organisms. Based on the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) system and CRISPR-associated (Cas) proteins, particularly Cas9, this technology is widely used in gene therapy, biomedical research, agriculture, and drug discovery.
Download a Free Sample To learn more about this report,
Shift From Gene Disruption to Precise Gene Correction
The need for greater precision and safety in genome modification is shifting the market from conventional gene disruption toward targeted gene correction, with base and prime editing enabling specific DNA changes without relying on traditional double-strand breaks; a 2025 preclinical study achieved more than 60% in vivo base editing of the Angptl3 gene in mice using lipid nanoparticles.
Rise of In Vivo CRISPR Therapies
Advances in delivery technologies are moving CRISPR therapies from ex vivo cell modification toward in vivo editing, allowing gene-editing components to be administered directly to targeted tissues; by December 2025, 36 of 136 ongoing CRISPR trials used in vivo delivery, indicating growing clinical activity in this approach.
Growing Burden of Genetic Disorders and Increasing Investment in Rare Disease Therapies Drive Market
The rising burden of genetic disorders increases demand for CRISPR-based research and therapeutic development, particularly for conditions with limited treatment options. Rare diseases such as sickle cell disease, beta-thalassemia, and Duchenne muscular dystrophy create a strong need for therapies that address underlying genetic causes. Clinical applications such as CRISPR-based treatment approaches for sickle cell disease demonstrate the potential of gene editing in inherited disorders. Growing patient needs encourage pharmaceutical companies and research institutions to expand CRISPR programs and clinical studies. The broader disease pool therefore increases demand for CRISPR enzymes, guide RNAs, delivery systems, and gene-editing services.
Higher investment in rare disease research increases funding for CRISPR programs aimed at developing treatments for conditions with small but clinically significant patient populations. Greater pharmaceutical and biotechnology involvement expands the pipeline of gene-editing candidates and increases demand for specialized research platforms and reagents. Applications such as CRISPR-based therapies targeting blood disorders and inherited metabolic diseases highlight the growing commercial focus on rare conditions. Increased funding also supports clinical trials, manufacturing development, and regulatory activities around gene-editing therapies. The expanding development pipeline strengthens demand across the CRISPR research and therapeutic supply chain.
Off-Target Editing and Unintended Genetic Changes and Limited Long-Term Safety Data Restrain Market Expansion
Unintended edits at genomic sites outside the intended target can create unwanted genetic changes and raise safety concerns for CRISPR-based applications. These risks require extensive screening, validation, and optimization to improve editing accuracy before clinical or commercial use. Such technical limitations can increase development timelines and costs, while reducing confidence in broader CRISPR adoption.
Limited long-term safety data makes it difficult to assess the durability and potential delayed effects of CRISPR-induced genetic changes over extended periods. Researchers and regulators require longer follow-up to evaluate risks such as unintended genomic effects and immune responses. This uncertainty can slow regulatory approvals, clinical adoption, and investment in CRISPR-based therapies.
Development of CRISPR Research Tools and Reagents and Increasing Demand for Gene Editing Contract Services Offer Growth Opportunities
Research institutes, biotechnology firms, and pharmaceutical companies represent key customers for CRISPR enzymes, guide RNAs, vectors, and screening kits used in gene-editing studies. Companies such as Merck KGaA and Thermo Fisher Scientific can expand revenue through recurring reagent sales and specialized research products.
Biotech startups and pharmaceutical developers can outsource gene-editing experiments to specialized providers that offer cell engineering, screening, and preclinical research support. Companies such as Charles River Laboratories and Crown Bioscience can gain revenue from project-based services and long-term development partnerships.
Challenges in Delivering CRISPR Components to Target Cells and Difficulty in Scaling CRISPR Manufacturing Hinders Growth
Efficiently delivering CRISPR systems to specific tissues and cells remains difficult, particularly for organs that are hard to access with current viral and non-viral vectors. For example, liver-directed therapies have progressed faster than delivery to tissues such as the brain and muscle, limiting the number of diseases that companies can address with CRISPR products.
Producing gene-editing components at consistent quality and commercial scale is challenging because therapies may require complex guide RNAs, Cas proteins, viral vectors, or lipid nanoparticles. The manufacturing complexity seen in clinical-stage CRISPR therapies such as Casgevy illustrates the need for specialized production and quality-control capabilities, which can slow broader commercialization.
The CRISPR Products segment accounted for a market share of 62.4% in 2025 due to their widespread use in gene-editing research, including CRISPR kits, reagents, enzymes, and related laboratory tools. Growing adoption of ready-to-use CRISPR products across academic, pharmaceutical, biotechnology, and genomic research laboratories further supports the segment's dominant position.
The CRISPR Products accounted for a share of 62.4% in 2025 due to their widespread use in gene-editing research, including CRISPR kits, reagents, enzymes, and related laboratory tools. Growing demand for ready-to-use and standardized gene-editing components supports their adoption across academic, pharmaceutical, biotechnology, and research laboratories. The availability of products for applications such as gene knockout, gene activation, screening, and targeted genome modification further strengthens the segment's market position.
Request Customizationto receive a tailored report.
The biomedical segment accounted for a share of 31.6% in 2025 due to the extensive use of CRISPR gene editing in disease research, therapeutic development, drug discovery, and molecular diagnostics. Growing research on genetic disorders and the development of gene-editing-based treatments are increasing demand for CRISPR technologies in biomedical applications. Advances in targeted gene modification further support its adoption across pharmaceutical, biotechnology, and academic research.
The agricultural segment is supported by the growing use of CRISPR technology to develop crops with improved yield, disease resistance, stress tolerance, and nutritional characteristics. Increasing demand for climate-resilient and productive crops is encouraging researchers and agricultural biotechnology companies to adopt precise gene-editing techniques. The industrial segment benefits from the use of CRISPR in microbial engineering, enzyme production, bio-based manufacturing, and other industrial biotechnology applications. Increasing demand for optimized biological production systems is encouraging the development of engineered microorganisms with improved productivity and process efficiency. The genome engineering segment is driven by the growing need for precise modification of specific DNA sequences in research and biotechnology applications. CRISPR enables targeted gene insertion, deletion, and modification, supporting applications ranging from functional studies to the development of engineered cell lines.
The disease models segment is gaining adoption as CRISPR enables researchers to create precise genetic modifications that replicate disease-associated mutations. Growing demand for accurate models in drug discovery, disease mechanism studies, and preclinical research is increasing the use of CRISPR-based disease models. The functional genomics segment is supported by increasing research aimed at understanding gene function and gene–phenotype relationships. CRISPR-based knockout, activation, and repression techniques enable researchers to study large numbers of genes systematically, supporting applications in drug discovery and biological research.
The academic institutes and research centres accounted for a share of 34.8% in 2025 due to the extensive use of CRISPR technology in basic research, functional genomics, disease modelling, and gene-editing studies. Increasing research activities in molecular biology and genetics, along with access to specialized research infrastructure, support the adoption of CRISPR tools in these institutions. The growing number of genome-editing projects and collaborations with biotechnology and pharmaceutical companies further contributes to segment demand. The biotechnology companies segment is supported by increasing use of CRISPR technology in therapeutic development, diagnostics, agricultural biotechnology, and engineered biological systems. Growing investment in gene-editing platforms and the development of CRISPR-based products are increasing demand for specialized editing tools and services. The expansion of biotechnology pipelines further supports segment growth.
The Contract Research Organizations (CROs) segment is driven by rising outsourcing of gene-editing experiments, preclinical research, and genomic testing by pharmaceutical and biotechnology companies. CRISPR capabilities allow CROs to provide specialized research services without requiring clients to build extensive in-house infrastructure. The pharmaceutical and biopharmaceutical companies segment is supported by growing application of CRISPR in drug discovery, target validation, functional genomics, and development of gene-editing therapies. Increasing investment in precision medicine and advanced therapeutic platforms is expanding the use of CRISPR technologies across pharmaceutical research pipelines.
Speak to an Analystto discuss market opportunities.
The region is further supported by the growing clinical development of gene-editing therapies, with the U.S. FDA reporting that multiple cell and gene therapy products are advancing through clinical development and issuing new 2026 guidance to support genome-editing studies, which is expected to encourage continued research and commercialization activity.
The United States CRISPR gene editing market is expected to benefit from continued government-supported translational research, with the NIH’s Somatic Cell Genome Editing program advancing clinical development through FY2027, including platform clinical trials and targeted delivery technologies, while its TARGETED Challenge provides $6 million to develop improved in-vivo genome-editing delivery systems. The Canada CRISPR gene editing market is expected to benefit from expanding genomics and life-sciences investment, with the Canadian government planning C$41.1 million in Genome Canada contributions for 2026–27 and C$32.1 million for 2027–28, while a further C$99 million investment in life-sciences companies announced in August 2026 is strengthening domestic biotechnology capacity.
Unlock Regional Insightsto access country-level data, & regional trends.
The European CRISPR gene editing market is expected to grow at a CAGR of 18.6% during the forecast period, making it the fastest-growing regional market, supported by increasing investment in genomic medicine, expansion of clinical gene-editing research, and European initiatives aimed at strengthening biotechnology and advanced therapy development.
The U.K. CRISPR gene editing market is expected to benefit from expanding genomics infrastructure, with the U.K. Government targeting more than £650 million in funding for Genomics England by 2030 to support a genomic research database containing over 500,000 genomes, while the wider life-sciences sector is projected to grow by £41 billion by 2035, supporting continued development of gene-editing research and therapies. The Germany CRISPR gene editing market is expected to benefit from rising biotechnology R&D investment, with Germany recording €4.6 billion in medical-biotechnology R&D spending in 2024 and the federal government planning to increase research and development investment under its infrastructure and climate-neutrality fund by 60% in 2027 compared with 2026, strengthening the research base for advanced genomic technologies. The France CRISPR gene editing market is expected to benefit from continued biotherapy development, with France 2030 supporting €800 million for biotherapies and innovative therapy bioproduction and targeting the development and production of innovative therapies in France by 2030, while a clinical-pipeline study projects 44 new cell and gene therapies to reach the French market by 2030.
The Asia Pacific CRISPR gene editing market accounted for a market share of 20.4% in 2025, supported by expanding genomics research, increasing investment in biotechnology infrastructure, and growing adoption of gene-editing technologies across healthcare and research applications; the WHO also reports that countries in the Western Pacific are strengthening genomics infrastructure, national sequencing initiatives, and skilled workforces, creating a stronger ecosystem for advanced genomic technologies.
The China CRISPR gene editing market is expected to benefit from expanding biotechnology investment, with China targeting more than 10 trillion yuan in combined output from six emerging pillar industries by 2030, including biomedicine, while biotechnology is identified as a strategic field under the 2026–2030 national development plan, supporting continued investment in advanced genomic technologies. The Japan CRISPR gene editing market is expected to benefit from expanding biotechnology investment, with Japan targeting ¥3 trillion in annual domestic biotechnology-related investment by 2030 and a ¥92 trillion expansion in the biomanufacturing market by 2030, creating a stronger funding and commercialization environment for gene-editing applications.
The South Korea CRISPR gene editing market is expected to benefit from continued biotechnology infrastructure development, with the government planning to establish AI-powered biotechnology research hubs and autonomous laboratories by 2030 and develop AI-driven biotechnology models across five key areas, supporting advanced genomic research and gene-editing applications. The India CRISPR gene editing market is expected to benefit from rapid biotechnology expansion, with India targeting a $300 billion bioeconomy by 2030 and deploying a ₹1 lakh crore Research, Development and Innovation Fund, while the BioE3 Policy provides financial assistance of up to 70% of project costs for biotechnology infrastructure and innovation.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Organ Preservation Market Size, Share, Growth, Analysis, Report, 2034
Bacteriophage Market Size, Share, Growth, Analysis, 2034
Epigenetics Market Size, Share, Growth, Analysis, Report, 2034
Biobanking Market Size, Share, Growth, 2034
Cell Therapy Manufacturing Market Size, Share, Growth, 2034
Clinical Oncology Next Generation Sequencing Market Size, 2034
We are featured on:
sales@straitsresearch.com